OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
João Sérgio Neves, Marta Borges‐Canha, Francisco Vasques‐Nóvoa, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 6, pp. 517-525
Closed Access | Times Cited: 33
João Sérgio Neves, Marta Borges‐Canha, Francisco Vasques‐Nóvoa, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 6, pp. 517-525
Closed Access | Times Cited: 33
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
João Pedro Ferreira, Abhinav Sharma, Javed Butler, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 1, pp. 4-9
Open Access | Times Cited: 30
João Pedro Ferreira, Abhinav Sharma, Javed Butler, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 1, pp. 4-9
Open Access | Times Cited: 30
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
What is the evidence regarding the safety of new obesity pharmacotherapies
Josép Vidal, Lílliam Flores, Amanda Jiménez, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 8
Josép Vidal, Lílliam Flores, Amanda Jiménez, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 8
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
João Sérgio Neves, Faı̈ez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 12, pp. 1119-1122
Closed Access | Times Cited: 7
João Sérgio Neves, Faı̈ez Zannad, Javed Butler, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 12, pp. 1119-1122
Closed Access | Times Cited: 7
Obesity and Weight Loss Strategies for Patients With Heart Failure
Amanda R. Vest, Philip R. Schauer, Jo E. Rodgers, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 9, pp. 1509-1527
Closed Access | Times Cited: 6
Amanda R. Vest, Philip R. Schauer, Jo E. Rodgers, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 9, pp. 1509-1527
Closed Access | Times Cited: 6
Semaglutide and Cardiovascular Outcomes
A. Michael Lincoff, Donna H. Ryan, Sille Esbjerg
New England Journal of Medicine (2024) Vol. 390, Iss. 8, pp. 766-769
Closed Access | Times Cited: 4
A. Michael Lincoff, Donna H. Ryan, Sille Esbjerg
New England Journal of Medicine (2024) Vol. 390, Iss. 8, pp. 766-769
Closed Access | Times Cited: 4
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP /GLP ‐1 RA in type 2 diabetes
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 4
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 4
Antiobesity Medications in Patients With Heart Failure
Sureya F Hussani, Kelly Nguyen, Ka Man Yu, et al.
JACC Heart Failure (2025)
Closed Access
Sureya F Hussani, Kelly Nguyen, Ka Man Yu, et al.
JACC Heart Failure (2025)
Closed Access
SLEEVE GASTRECTOMY AS A BRIDGE TO CARDIAC RECOVERY - A RETROSPECTIVE COMPARATIVE COHORT STUDY
Thomas Goubar, Samuel S. Kim, David Cistulli, et al.
JHLT Open (2025) Vol. 8, pp. 100224-100224
Open Access
Thomas Goubar, Samuel S. Kim, David Cistulli, et al.
JHLT Open (2025) Vol. 8, pp. 100224-100224
Open Access
Effects of semaglutide on heart failure outcomes
João Sérgio Neves, Milton Packer, João Pedro Ferreira
The Lancet (2025) Vol. 405, Iss. 10478, pp. 542-543
Closed Access
João Sérgio Neves, Milton Packer, João Pedro Ferreira
The Lancet (2025) Vol. 405, Iss. 10478, pp. 542-543
Closed Access
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Thomaz Alexandre Costa, Josephine Harrington
Current Opinion in Cardiology (2025)
Closed Access
Thomaz Alexandre Costa, Josephine Harrington
Current Opinion in Cardiology (2025)
Closed Access
Cardiovascular effects of anti-obesity medications: the perils and promise
Haoyi Zheng
Cardiology Plus (2025)
Open Access
Haoyi Zheng
Cardiology Plus (2025)
Open Access
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Jiani Zhong, Hang Chen, Qiming Liu, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 14, Iss. 5, pp. 100917-100917
Open Access | Times Cited: 9
Jiani Zhong, Hang Chen, Qiming Liu, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 14, Iss. 5, pp. 100917-100917
Open Access | Times Cited: 9
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond
Wael Zaher, Domenico G. Della Rocca, Luigi Pannone, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1316-1316
Open Access | Times Cited: 3
Wael Zaher, Domenico G. Della Rocca, Luigi Pannone, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1316-1316
Open Access | Times Cited: 3
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Josephine Harrington, Stormi E. Gale, Amanda R. Vest
Circulation Heart Failure (2024) Vol. 17, Iss. 9
Closed Access | Times Cited: 3
Josephine Harrington, Stormi E. Gale, Amanda R. Vest
Circulation Heart Failure (2024) Vol. 17, Iss. 9
Closed Access | Times Cited: 3
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Role of anti‐obesity drugs in heart failure regardless of ejection fraction
Javed Butler, Muhammad Sameer Arshad, Muhammad Shahzeb Khan
European Journal of Heart Failure (2024) Vol. 26, Iss. 8, pp. 1703-1706
Closed Access | Times Cited: 2
Javed Butler, Muhammad Sameer Arshad, Muhammad Shahzeb Khan
European Journal of Heart Failure (2024) Vol. 26, Iss. 8, pp. 1703-1706
Closed Access | Times Cited: 2
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, et al.
Medicina (2024) Vol. 60, Iss. 6, pp. 912-912
Open Access | Times Cited: 2
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, et al.
Medicina (2024) Vol. 60, Iss. 6, pp. 912-912
Open Access | Times Cited: 2
Epicardial fat in heart failure—Friend, foe, or bystander
Aleksandra Paterek, Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, et al.
Obesity Reviews (2024) Vol. 25, Iss. 12
Open Access | Times Cited: 2
Aleksandra Paterek, Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, et al.
Obesity Reviews (2024) Vol. 25, Iss. 12
Open Access | Times Cited: 2
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
João Sérgio Neves, Ana Rita Leite, Robert J. Mentz, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 2
João Sérgio Neves, Ana Rita Leite, Robert J. Mentz, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 2
Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis
Mainak Banerjee, Indira Maisnam, Satinath Mukhopadhyay
Cardiovascular Drugs and Therapy (2023) Vol. 38, Iss. 4, pp. 739-746
Closed Access | Times Cited: 6
Mainak Banerjee, Indira Maisnam, Satinath Mukhopadhyay
Cardiovascular Drugs and Therapy (2023) Vol. 38, Iss. 4, pp. 739-746
Closed Access | Times Cited: 6
Epicardial fat and ventricular arrhythmias
Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, Małgorzata Kalisz, et al.
Heart Rhythm (2023) Vol. 21, Iss. 2, pp. 206-212
Closed Access | Times Cited: 5
Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, Małgorzata Kalisz, et al.
Heart Rhythm (2023) Vol. 21, Iss. 2, pp. 206-212
Closed Access | Times Cited: 5
A review of current key guidelines for managing high‐risk patients with diabetes and heart failure and future prospects
Matthew M.Y. Lee, Naveed Sattar
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. S3, pp. 33-47
Open Access | Times Cited: 4
Matthew M.Y. Lee, Naveed Sattar
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. S3, pp. 33-47
Open Access | Times Cited: 4
